Nasdaq Prld News Today

Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at...

Prelude Therapeutics Incorporated (NASDAQ:PRLD – Get Free Report) was the target of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 522,000 shares, an increase of 15.6% from the January 15th total of 451,500 shares. Based on an average trading volume of 141,000 shares, […]

WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision...

Prelude Therapeutics Incorporated (NASDAQ:PRLD – Free Report) – Stock analysts at HC Wainwright issued their Q1 2024 earnings estimates for Prelude Therapeutics in a research note issued on Thursday, August 17th. HC Wainwright analyst R. Burns forecasts that the company will earn ($0.61) per share for the quarter. HC Wainwright currently has a “Buy” rating […]

Prelude Therapeutics (NASDAQ:PRLD – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They currently have a $17.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 376.19% from the stock’s previous close. Other equities […]

Prelude Therapeutics Incorporated (NASDAQ:PRLD – Get Free Report) saw a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 2,130,000 shares, a decline of 20.5% from the July 15th total of 2,680,000 shares. Based on an average trading volume of 121,300 shares, the days-to-cover ratio […]

Prelude Therapeutics (NASDAQ:PRLD – Free Report) had its target price reduced by Barclays from $7.00 to $5.00 in a research note released on Friday, Marketbeat Ratings reports. They currently have an equal weight rating on the stock. Prelude Therapeutics Stock Performance Shares of Prelude Therapeutics stock opened at $3.67 on Friday. Prelude Therapeutics has a […]

Prelude Therapeutics Incorporated (NASDAQ:PRLD – Get Rating) Director Orbimed Advisors Llc acquired 869,565 shares of the firm’s stock in a transaction on Monday, May 22nd. The stock was purchased at an average cost of $5.75 per share, with a total value of $4,999,998.75. Following the purchase, the director now owns 10,119,756 shares of the company’s […]

Prelude Therapeutics Incorporated (NASDAQ:PRLD – Get Rating) Director Orbimed Advisors Llc acquired 869,565 shares of the company’s stock in a transaction on Monday, May 22nd. The stock was bought at an average price of $5.75 per share, for a total transaction of $4,999,998.75. Following the purchase, the director now owns 10,119,756 shares in the company, […]

WILMINGTON, Del., May 17, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or the “Company”) (Nasdaq: PRLD), a clinical-stage...